Affimed Scraps Mono AFM13 To Focus on Combinations
Insights - Affimed (AFMD) gave an update at the ASH conference this weekend for their AFM13 program in both monotherapy and combination w/ NK. The monotherapy data … Continue Reading
PremiumSearch Results for gene therapy
Affimed Announced Artiva as NK Cell Partner
Insights - Affimed announced an early peek at updated AFM13+NK data that will be presented at ASH conference on December 10, 2022. The data was strong. Importantly, … Continue Reading
PremiumA Look At AFMD Ahead of Q4 2022 Catalysts
Insights - Affimed gave a Q2 2022 business update which was mixed. Their second half is expected to have a few catalysts, but the company also announced … Continue Reading
Premium
Milestone Pharma Attractive Ahead of Phase 3 Data
Insights - The XBI is seeing life as M&A activity is picking up. Last week Amgen acquired ChemoCentryx (CCXI) for $3.7B in cash, with the idea being … Continue Reading
Premium
Mid-Year Update on Holdings
Research - It has been an eventful week for a few of our holdings. Quick update on each name below. Affimed Update on Manufacturing StrategyWe spoke to … Continue Reading
Premium
Bio Seeing Early Life After ASCO 2022 & Big Acquisitions
Insights - The bio sector is seeing some life with improved fundamentals, which could be an early sign of reversal. ASCO in Chicago is wrapping up and … Continue Reading
PremiumAFMD Prioritizing Combo Programs
Insights - The XBI biotech index was starting a see some consolidation during February in the low-mid $90s. However, that was interrupted by the ongoing tensions between … Continue Reading
Premium